IBRX - סך החוב של החברה ImmunityBio

ImmunityBio, Inc. (IBRX) is scaling Anktiva sales and penetrating new NK-cell niches. The total liabilities trend visualizes the financial burden, where 0.00 reflects the latest metric value. The operating model relies on full outsourcing of production and testing through external partners, while the R&D center aggressively advances IL-15 research to maximize the company's innovation potential.

Developing innovative vaccines in immuno-oncology requires significant capital, making debt load control critical for the financial stability of ImmunityBio, Inc. (IBRX). This indicator aggregates obligations to creditors and bondholders, eliminating reporting time gaps for accurate solvency monitoring, which allows the investor to assess the balance between business scaling and debt burden via the total debt chart.